Overview
- Released January 11, the FDA’s update outlines flexible oversight across clinical development, commercial specifications, and process validation for cell and gene therapies.
- Sponsors are not expected to meet 21 CFR part 211 before manufacturing for phase 2 or 3 trials, and investigational lots may use permissive release criteria with minor manufacturing changes allowed when supported by comparability data.
- During BLA review, the agency will consider product‑specific flexibility in setting release specifications and may permit post‑approval revisions based on demonstrated manufacturing consistency.
- Process validation no longer presumes three PPQ lots, with batch‑by‑batch qualification and concurrent release possible when adequately justified.
- FDA leaders described the approach as common‑sense reforms responding to rapid growth in CGT submissions, while regulatory analysts noted the flexibilities are case‑by‑case practices now made more explicit with further guidance potentially to come.